Key Points
- Mural Oncology insider Vicki Goodman sold 5,036 shares at an average price of $2.08 for $10,474.88, reducing her stake by 5.61% to 84,727 shares, according to an SEC filing.
- MURA shares trade around $2.10 (50‑day $2.08, 200‑day $2.28) with a market cap of about $36.4M, a beta of 2.93, and a one‑year range of $0.95–$4.74.
- The company reported quarterly EPS of −$0.21, beating estimates of −$0.59, while analysts hold a consensus Hold rating with an average $12 target amid mixed opinions; institutional investors own roughly 80% of the stock.
Mural Oncology PLC (NASDAQ:MURA - Get Free Report) insider Vicki Goodman sold 5,036 shares of the company's stock in a transaction on Monday, November 10th. The stock was sold at an average price of $2.08, for a total transaction of $10,474.88. Following the completion of the transaction, the insider directly owned 84,727 shares in the company, valued at $176,232.16. This trade represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Mural Oncology Trading Up 0.5%
MURA opened at $2.10 on Tuesday. The stock has a fifty day moving average price of $2.08 and a 200 day moving average price of $2.28. Mural Oncology PLC has a 1 year low of $0.95 and a 1 year high of $4.74. The stock has a market cap of $36.41 million, a price-to-earnings ratio of -0.30 and a beta of 2.93.
Mural Oncology (NASDAQ:MURA - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.38. As a group, sell-side analysts forecast that Mural Oncology PLC will post -7.54 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Mural Oncology
A number of large investors have recently added to or reduced their stakes in MURA. Concurrent Investment Advisors LLC bought a new position in shares of Mural Oncology in the first quarter valued at approximately $28,000. Quadrature Capital Ltd acquired a new position in Mural Oncology in the 2nd quarter valued at $98,000. Rangeley Capital LLC acquired a new position in Mural Oncology in the 2nd quarter valued at $115,000. BML Capital Management LLC bought a new position in Mural Oncology in the 3rd quarter worth $119,000. Finally, F m Investments LLC acquired a new position in Mural Oncology during the 2nd quarter worth $192,000. Institutional investors own 80.21% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on MURA shares. Wall Street Zen cut shares of Mural Oncology from a "hold" rating to a "strong sell" rating in a research note on Sunday, August 10th. Weiss Ratings restated a "sell (e+)" rating on shares of Mural Oncology in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $12.00.
View Our Latest Report on Mural Oncology
Mural Oncology Company Profile
(
Get Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
